依达拉奉联合丁苯酞软胶囊治疗方案在脑梗塞患者中的疗效与应用研究

Study on the Efficacy and Application of Edaravone Combined with Butylphthalide Soft Capsule in Patients with Cerebral Infarction

目的探究依达拉奉联合丁苯酞软胶囊治疗方案在脑梗塞患者中的疗效与应用。方法择选该院2018年1月—2019年1月收治的80例脑梗塞患者为研究对象,基于完全随机原则进行分组,均分为研究组和对照组两组,每组40例。其中,对照组所有患者均接受常规治疗方案,研究组所有患者均接受依达拉奉联合丁苯酚软胶囊治疗方案。分别就两组患者治疗后的生活自理能力、神经功能进行对比,评价两组方案的治疗效果,并对比两组患者不良反应发生情况,对比两组方案的安全性。结果治疗后,研究组治疗有效率为95.0%,明显高于对照组75.0%,差异有统计学意义(χ^2=6.274,P<0.05);接受治疗后,研究组患者并无神经功能重度功能障碍患者,中度功能障碍2例,生活自理和轻度功能障碍38例,对照组神经功能重度功能障碍患者4例,中度功能障碍5例,生活自理和轻度功能障碍31例,研究组生活自理和轻度功能障碍为95.0%,明显高于对照组77.5%,差异有统计学意义(χ^2=5.164,P<0.05);研究组仅有1例患者出现食欲减退的不良反应;对照组有2例患者出现不良反应,分别是皮疹和恶心。两组患者在不良反应发生率方面的对比,差异无统计学意义(χ^2=0.000,P>0.05)。结论脑梗塞患者接受依达拉奉联合丁苯酚软胶囊治疗方案,可有效提高治疗有效率,改善患者生活自理情况,且拥有较高的安全性,具有较高的应用推广价值。

Objective To explore the efficacy and application of edaravone combined with butylphthalide soft capsules in patients with cerebral infarction. Methods Eighty patients with cerebral infarction admitted to the hospital from January 2018 to January 2019 were selected as the research objects. They were grouped based on the principle of complete randomization. They were divided into two groups: the study group and the control group, with 40 cases in each group. Among them, all patients in the control group received conventional treatment, and all patients in the study group received edaravone combined with butyl phenol soft capsule treatment. The self-care ability and neurological function of the two groups of patients after treatment were compared, the treatment effects of the two groups were evaluated, and the occurrence of adverse reactions between the two groups of patients was compared, and the safety of the two groups was compared. Results After treatment, the effective rate of treatment in the study group was 95.0%,which was higher than 75.0% in the control group, the difference was statistically significant(χ^2=6.274, P<0.05);after treatment, patients in the study group had no patients with severe neurological dysfunction, 2 patients with moderate dysfunction, 38 patients with self-care and mild dysfunction, in the control group 4 patients with severe neurological dysfunction, 5 patients with moderate dysfunction, self-care and mild dysfunction of 31 cases of disorders, the study group’s self-care and mild dysfunction were 95.0%, which was significantly higher than the control group’s 77.5%,difference was statistically significant(χ^2=5.164, P<0.05);Among the 40 patients in the study group, only one patient had adverse reactions of loss of appetite;two of the 40 patients in the control group had adverse reactions, namely rash and nausea. There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(χ^2=0.00, P>0.05). Conclusion The treatment of edaravone combined with butyl phenol soft capsules for patients with cerebral infarction can effectively improve the treatment efficiency, improve the patient’s self-care situation, and has high safety and high application promotion value.